Orthostatic hypotension (OH) is common in Parkinson’s disease (PD) and 30-50% of patients suffer with it.1-2 OH can be symptomatic or asymptomatic and according to Palma et al 16% of these patients with OH are symptomatic.3 

Those patients with symptoms will feel dizziness, unsteadiness and light-headedness on standing up leading to a fall and possibly loss of consciousness. They can also complain of fatigue and pain in the neck and shoulders called coat hanger pain when they are up and about. Characteristically these symptoms get better on sitting down. It is uncommon to have symptoms of OH while sitting down.

Symptoms of cerebral hypo-perfusion emerge when blood pressure (BP) standing falls below the lower limit of the cerebral auto-regulatory range and this usually occurs when mean BP standing is <75mmHg, which corresponds to ~90/60mmHg (systolic/diastolic) at the heart level.3

These symptoms can lead to recurrent falls, significant morbidity, at times and mortality and can effect activities of daily living.4,5 On the other hand, a significant proportion of patients with OH will have supine hypertension (SH), defined as a systolic BP≥150mmHg and diastolic BP ≥90mmHg and can lead to end organ damage and is a limiting factor in the treatment.6 Hence it is important to actively look for these autonomic changes in PD and manage them accordingly.

Mechanism of orthostatic hypotension and supine hypertension

In PD, OH is considered to be a neurotransmitter disorder as degeneration of postganglionic efferent sympathetic neurons lead to impaired release of norepinephrine and defective vasoconstriction on standing up, hence low blood pressure.3

The mechanism for SH is unclear. Increased vascular resistance due to residual sympathetic activity has been suggested in Multisystem Atrophy (MSA).7

Clinical approach to Parkinson's disease patients with supine hypertension

Correct diagnosis of OH can only be possible with screening all PD patients with proper lying BP and then immediate standing and three minutes standing. Patient should have rested lying down for 10 minutes before lying BP is taken. By definition OH is a sustained reduction of systolic blood pressure of at least 20 mmHg or diastolic blood pressure of 10mmHg, or both, within three minutes of standing or head-up tilt to at least 60⁰ on a tilt table.8 

If three minutes standing is not diagnostic then the screening should be prolonged to 10 minutes standing. If these measurements are not helpful in diagnosing and patient has got symptoms of OH then home BP monitoring or 24 hours BP monitoring can be informative and it will also be valuable in diagnosing post prandial hypotension and supine hypertension.

Prolonged tilt table test at times needs to be done to diagnose and in specialist centres autonomic reflex testing, plasma fractionated catecholamine levels and sudomotor function testing can be asked for the diagnosis.9 Orthostatic Hypotension Questionnaire has been validated since 2012 and will provide further evidence.10

Treatment of orthostatic hypotension

Medication review

The first important step in the treatment should be to review PD patients’ medications. Anti-hypertensive especially diuretics and vasodilators, alpha blockers for urinary symptoms and antidepressants are commonly responsible for OH. Also antiparkinsonian medications can lower BP so there doses should be adjusted accordingly.

Physical measures

Patients should be counselled to:

  • Put extra salt in diet (6-10gm/day)
  • Intake of at least 2 litres of fluid per day
  • Taking boluses of 500mls of very cold water
  • Stand up slowly from lying and sitting position and cross legs when sitting
  • Sleep with head of the bed raised to 45⁰
  • Avoid large sugary meals with alcohol as it can cause post prandial hypotension and divide the meals into 4-5 smaller meals.
  • Abdominal binders have been shown to be effective by reducing splanchnic venous pooling11 but knee high compression stocking are cumbersome for older patients hence not effective.12

Pharmacological measures

If medication review and physical measures are not effectively controlling OH then consideration should be given to the pharmacological measures. One of the therapeutic challenges will be SH as Palma et al study showed that 44% of PD patients has supine BP greater than 140/90 mmHg.3 Another study showed that 71.1% of PD patients with OH had no proper circadian rhythm as compare to that of the control population (48%). The prevalence of the non-dipper or riser patterns was higher in patients with orthostatic hypotension (77.8 vs. 66.7%).13

Choice of pharmacological agents should be tailored according to patient’s needs, comorbidities and potential side effects of those medications.

Fludrocortisone is a synthetic mineralocorticoid and increases renal sodium and water absorption hence expanding the intravascular volume and helping in OH. It takes 7-10 days to cause its clinical effect. It is advised that the dosage should never be more than 0.2mg/day because it doesn’t increase the efficacy of the drug and causes side effects with hypokalemia, ankle oedema and worsening of heart failure14 and long term use is associated with higher risk of hospitalizations in patients with OH.15

Midodrine is α1–adrenoceptor agonist and causes vasoconstriction leading to increase in BP. Treatment should begin with small dose of 2.5mg three times a day and can be increased later on until 10mg three times a day. It is well tolerated with usual side effects of pilo-erection, itching of scalp and urinary retention. It is best taken before getting out of bed, around midday and mid-afternoon, avoiding it before going to bed as there is risk of SH.

Droxidopa is a noradrenaline precursor that is converted into noradrenaline by the dopa-decarboxylase. Droxidopa has been shown to be to improve OH symptoms with one to two weeks treatment in PD patients in placebo controlled trials16,17 and a recent paper of Francois et al showed that fewer OH patients reported falling after one, three, and six months of droxidopa treatment and further improvements reported in OH symptoms, physical function, and QOL measures were maintained for six months following treatment initiation.18 

The starting dose is 100mg three times per day and can be titrated to 1800mg per day. It is now approved for OH in United States for PD, MSA and pure autonomic failure but not yet available in Europe.  

DOPA decarboxylase inhibitors (DDCI, eg. carbidopa) can block the conversion of droxidopa to norepinephrine and decrease theoretically the efficacy of droxidopa but more studies are needed specifically to address this issue. In practice, patients receiving droxidopa still had an increase in their blood pressure and symptomatic improvement when taking DDCI at clinically indicated dosages.

Atomoxetine is a norepinephrine reuptake inhibitor and increases the availability of norepinephrine at the neurovascular junction. Small trials have shown it to be effective in PD but more so in pure autonomic failure19 and in fact superior in improving upright systolic BP and symptoms related to OH when compared with midodrine.20 

Pyridostigmine, a cholinesterase inhibitor has got modest effect and at times is combined with midodrine or atomoxetine but has got lot of gastrointestinal side effects.21 

Yohimbine, dihydroergotamine and psuedoehpedrine are rarely used now a days because of their side effects profile. There are also anecdotal evidence for domperidone use in OH but QT prolongation should be considered beforehand.22

Recombinant Erythropoietin for the patients with anaemia has a positive influence on OH with improvement in anaemia and increases blood pressure.23

Treatment of supine hypertension

Treatment for SH can be challenging but patients should avoid napping in supine position in the daytime and presser agents like midodrine should be preferred as compare to fludrocortisone and the last dose administration should be no later than 4pm. At night tilting up of the bed 30-45⁰ lowers the BP.

A snack before going to bed with alcohol can lower the BP. Pharmacological intervention for high BP overnight can be considered and should be in form of short acting anti-hypertensive like losartan, GTN patch or clonidine.24,25 One needs to be mindful about the effect of these ant-hypertensive in the daytime because they can cause OH.

Conclusion

Orthostatic hypotension is common in Parkinson’s disease. It can impair the quality of life and can lead to falls, morbidity and mortality. Its only when we are actively looking for it by doing proper lying and standing BP that we can diagnose it. Different treatment options are available and should be used to reduce the burden of illness as Parkinson’s.


Dr Jazia Rasheed, Associate specialist, Frailty Assessment unit, Yeovil hospital Foundation trust, Yeovil, Somerset.

Dr Waseem Ahmad Bashir, consultant geriatrician, care of older people, Yeovil hospital Foundation trust, Yeovil, Somerset.

Dr Rani Sophia, consultant geriatrician, Frailty Assessment unit, Yeovil hospital Foundation trust, Yeovil, Somerset.

Jazia.rasheed@ydh.nhs.uk

Conflict of interest: none


References

  1. Velseboer DC, de Haan RJ, Wieling W, et al. Prevalence of orthostatic hypotension in Parkinson’s disease: A systematic review and meta-analysis. Parkinsonism Relat Disord 2011; 17, 724-729
  2. Kaufmann H, Norcliffe-Kaufmann L, Palma JA, et al. Natural history of pure autonomic failure: A United States prospective cohort. Ann Neurol 2017; 81, 287-297
  3.  Palma JA, Gomez-Esteban JC, Norcliffe-Kaufmann L, et al. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go? Mov Disord 2015; Apr 15; 30(5):639-645. doi: 10.1002/mds.26079. Epub 2015 Feb 12.
  4.  Romagnolo A, Zibetti M, Merola A, et al. Cardiovascular autonomic neuropathy and falls in Parkinson disease: Aprospective cohort study. J Neurol 2019; 266, 85-91.
  5. Ten Harmsen BL, van Rumund A, Aerts MB, et al. Clinical correlates of cerebral white matter abnormalities in patients with Parkinson’s disease. Parkinsonism Relat Disord 2018; 49, 28-33.
  6.  Fanciulli A, Strano S, Colosimo C, Caltagirone C, Spalletta G, Pontieri FE. The potential prognostic role of cardiovascular autonomic failure in alpha-synucleinopathies. Eur J Neurol 2013; 20, 231-235.
  7.  Shannon J R,  Jordan J, Diedrich A, Pohar B, Black B K, Robertson D, Biaggioni I.  Sympathetically Mediated Hypertension in Autonomic Failure. Circulation 2000; 101: 2710–2715
  8. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci 2011;161(1–2):46–48.
  9. Gibbons, C.H., Schmidt, P., Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol 2017; 264, 1567–1582
  10. Kaufmann H, Malamut R, Norcliffe-Kaufmann L, et al. The Orthostatic Hypotension Questionnaire (OHQ): Validation of a novel symptom assessment scale. Clin Auton Res 2012; 22, 79-90
  11. Okamoto LE, Diedrich A, Baudenbacher FJ, et al. Efficacy of servocontrolled splanchnic venous compression in the treatment of orthostatic hypotension: A randomized comparison with midodrine. Hypertension 2016; 68, 418-426
  12. Newton JL, Frith J. The efficacy of nonpharmacologic intervention for orthostatic hypotension associated with aging.  Neurology 2018; 91, e652-e656
  13. Berganzo K, Diez-Arrola B, Tijero B, et al. Nocturnal hypertension and dysautonomia in patients with Parkinson’s disease: are they related? J Neurol 2013; 260:1752–6
  14. Palma J A, Kaufmann H. Orthostatic Hypotension in Parkinson Disease. Clin Geriatr Med -2019; vol 36, page 53-67
  15. Grijalva CG, Biaggioni I, Griffin MR, et al. Fludrocortisone is associated with a higher risk of all-cause hospitalizations compared with midodrine in patients with orthostatic hypotension. J Am Heart Assoc  2017; 6
  16. Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension:Arandomized, placebo-controlled, phase 3 trial. Neurology 2014; 83, 328-335.
  17. Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson’s disease (nOH306B). Mov Disord 2015; 30, 646-654
  18. Francois C, Shibao CA, Biaggioni I, et al. Six-month use of droxidopa for neurogenic orthostatic hypotension. Mov Disord Clin Pract 2019; 6, 235-242
  19. Okamoto LE, Shibao C, Gamboa A, et al. Synergistic effect of norepinephrine transporter blockade and alpha-2 antagonism on blood pressure in autonomic failure. Hypertension 2012; 59: 650–6
  20. Ramirez CE, Okamoto LE, Arnold AC, et al. (2014) Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension 2014; 64: 1235–40
  21. Okamoto LE, Shibao CA, Gamboa A, et al. Synergistic pressor effect of atomoxetine and pyridostigmine in patients with neurogenic orthostatic hypotension. Hypertension 2019; 73:235–41
  22. Lang A. (2001). Acute orthostatic hypotension when starting dopamine agonists in Parkinson’s disease: the Role of Domperidone Therapy (letter)Arch. Neurol 2001; 58, 835 10.1001/archneur.58.5.835
  23. Perera R, Isola L, Kaufmann H. Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure. Clin Auton Res 1995; 5, 211-213
  24. Shibao C, Gamboa A, Abraham R, Raj SR, Diedrich A, Black B, Robertson D, Biaggioni I. Clonidine for the treatment of supine hypertension and pressure natriuresis in autonomic failure. Hypertension 2006; 47, 522-526
  25. Shibao C, Gamboa A, Diedrich A, Biaggioni I. Management of hypertension in the setting of autonomic dysfunction. Curr Treat Options Cardiovasc Med 2006; 8, 105-109.